New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ZTS;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
November 26, 2014
10:43 EDTPFEMylan calls active after called 'most likely' Pfizer takeover target
Subscribe for More Information
10:34 EDTPFEMylan advances after called 'most likely' Pfizer takeover target
Subscribe for More Information
07:48 EDTPFEMylan now most likely takeover target for Pfizer, says Jefferies
Jefferies believes Mylan (MYL), following its combination with Abbott's (ABT) Developed Markets Established Products business, is now the most likely takeover target of Pfizer (PFE). The firm thinks Pfizer management is highly motivated to either merge with, invert into or acquire a foreign company. It believes Actavis (ACT) and AstraZeneca (AZN) are off the table as potential Pfizer targets given the former's takeover of Allergan (AGN) and latter's oncology deal with Merck KGaA (MKGAY). Jefferies calls GlaxoSmithKline (GSK) the "wild card" potential takeover target for Pfizer. The firm estimates Pfizer could pay a 25% premium for Mylan and have the deal be highly accretive.
07:30 EDTZTSZoetis takeover 'highly probable' event in 2015, says Jefferies
Jefferies sees a potential acquisition of Zoetis (ZTS) by another industry player like Bayer (BAYRY) as a "highly probable" event during 2015. The firm raised its price target for Zoetis shares to $53 from $46 and believes the company's 2015 guidance, while missing expectations, leaves room for upside. It keeps a Buy rating on the stock.
November 24, 2014
15:53 EDTZTSBayer working with Credit Suisse to explore diabetes unit sale, Bloomberg says
Subscribe for More Information
09:02 EDTZTSZoetis names Roman Trawicki as president of global manufacturing and supply
Subscribe for More Information
07:46 EDTPFEPfizer seen set to move on from AstraZeneca as restrictions lift, Telegraph says
Subscribe for More Information
November 20, 2014
10:02 EDTZTSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Zoetis (ZTS) downgraded to Market Perform from Outperform at William Blair... Target (TGT) downgraded to Hold from Buy at Evercore ISI... Alexandria Real Estate (ARE) downgraded to Neutral from Outperform at RW Baird... Allscripts (MDRX) downgraded to Sector Perform from Outperform at RBC Capital... athenahealth (ATHN) downgraded to Underperform from Sector Perform at RBC Capital... Boston Properties (BXP) downgraded to Neutral from Outperform at RW Baird... Cliffs Natural (CLF) downgraded to Hold from Buy at Deutsche Bank... Cubist (CBST) downgraded to Neutral from Outperform at Credit Suisse... Denbury Resources (DNR) downgraded to Equal Weight from Overweight at Barclays... E-House (EJ) downgraded to Perform from Outperform at Oppenheimer... Owens-Illinois (OI) downgraded to Market Perform from Outperform at BMO Capital... Quality Systems (QSII) downgraded to Sector Perform from Outperform at RBC Capital... Sapient (SAPE) downgraded to Hold from Buy at Stifel... Harsco (HSC) downgraded to Hold from Buy at Argus... Credit Acceptance (CACC) downgraded to Underperform from Market Perform at JMP Securities... Liberty Media (LMCA) downgraded to Hold from Buy at Telsey Advisory.
08:36 EDTZTSZoetis guidance positive, says BMO Capital
Subscribe for More Information
05:32 EDTZTSZoetis downgraded to Market Perform from Outperform at William Blair
Subscribe for More Information
November 19, 2014
08:19 EDTZTSZoetis price target raised to $55 from $45 at Guggenheim
Subscribe for More Information
07:52 EDTPFEInforma Business Information to hold a conference
Subscribe for More Information
06:56 EDTZTSZoetis price target raised to $48 from $41 at JPMorgan
Subscribe for More Information
06:39 EDTZTSZoetis price target raised to $50 from $43 at Piper Jaffray
Subscribe for More Information
November 18, 2014
18:15 EDTZTSAckman urges significant cost cuts at Zoetis, Bloomberg says
Subscribe for More Information
13:45 EDTZTSZoetis trading resumes, shares down 61c to $43.62
Subscribe for More Information
13:44 EDTZTSZoetis sees 'modest improvements' in gross margin ahead of 2017
Subscribe for More Information
13:43 EDTZTSZoetis sees 2016, 2017 net income growth 11%-16%
Subscribe for More Information
13:42 EDTZTSZoetis sees net income growth in low double-digits over long term
Zoetis said it believes it can grow adjusted net income in the low double-digits over the long term.
13:38 EDTZTSZoetis sees FY15 adjusted EPS $1.61-$1.68, consensus $1.71
Subscribe for More Information
13:32 EDTZTSZoetis trading halted, pending news
Subscribe for More Information
08:33 EDTPFEPfizer announces availability of Trumenba vaccine
Pfizer announced hat TRUMENBA, the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States.
07:55 EDTZTSZoetis price target raised to $50 from $41 at Argus
Argus increased its price target on Zoetis after Bill Ackman's firm disclosed that it had acquired an 8.5% stake in the company. The firm thinks that Ackman may search for a potential buyer of Zoetis. Argus also believes that the company's margins can rise, and it keeps a Buy rating on the shares.
07:29 EDTPFEPfizer less likely to pursue AstraZeneca after PD-L1 deal, says JPMorgan
Subscribe for More Information
07:18 EDTPFEWoodford confident in Astra, sees 50% chance of new Pfizer bid, Reuters reports
Investment manager Neil Woodford of Woodford Investment Management said he now has an even stronger belief in AstraZeneca (AZN), citing the company's strong product pipeline, and put the chances of a new takeover bid from Pfizer (PFE) at 50/50, reported Reuters, citing a statement from Woodford. Reference Link
07:00 EDTZTSZoetis announces authorization of $500M share repurchase program
Subscribe for More Information
06:49 EDTZTSValeant likely to pursue more moderate-sized deals, says Piper Jaffray
Subscribe for More Information
06:39 EDTPFEAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
14:27 EDTPFEPfizer volatility flat into investor meeting
Subscribe for More Information
10:40 EDTZTSZoetis to host investor day
Subscribe for More Information
09:42 EDTPFEPfizer to host investor day
Subscribe for More Information
09:22 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:16 EDTZTSZoetis to purchase assets of Abbott Animal Health for about $255M
Subscribe for More Information
08:15 EDTZTSZoetis to purchase assets of Abbott Animal Health for about $255M
08:13 EDTPFEPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
07:16 EDTPFEMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
06:43 EDTPFEAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
05:27 EDTPFEPfizer lowers FY14 Reported EPS view to $1.40-$1.49 from $1.50-$1.59
Subscribe for More Information
05:23 EDTPFEPfizer forms strategic alliance with Merck KGaA
Subscribe for More Information
November 14, 2014
17:14 EDTZTSPershing Square gives quarterly update on stakes
Subscribe for More Information
17:11 EDTZTSZoetis adopts poison pill to protect company from potential hostile takeover
Subscribe for More Information
14:53 EDTPFECVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:25 EDTZTSOptions with increasing implied volatility: BHI DWA ZTS
Subscribe for More Information
07:14 EDTPFEAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
11:28 EDTZTSOptions with increasing implied volatility: CVEO DWA ZTZ
Subscribe for More Information
09:36 EDTZTSZoetis downgraded to Neutral from Long-Term Buy at Hilliard Lyons
Subscribe for More Information
09:33 EDTZTSZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
07:38 EDTPFEBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use